Opioid addiction has reached pandemic levels in Canada, the United States and worldwide. The opioid crisis cost the US $696 billion in 2018 - or 3.4 percent of GDP - and more than $2.5 trillion for the period from 2015 to 2018. At all stages, it destroys lives and families.
Current treatment options for opioid and other forms of addiction do not work for most people. What’s missing is the ability to fast track the withdrawal process. Ibogaine - a molecule found in Tabernanthe iboga and many other plants - offers the opportunity for a rapid detox. In combination with an effective therapeutic setting, ibogaine offers the opportunity to live the good life again, free from addiction. Our goal is to provide safe, effective and affordable ibogaine treatment globally this decade.
Sign Up For News
Building a network of holistic recovery clinics focusing on the scientific application of ibogaine to treat the roots of addiction
To treat the roots of addiction effectively using ibogaine and other psychedelic medicines.
.svg)
Creating the gold standard for addiction treatment with ibogaine-assisted psychotherapy.
To provide those living with addiction the best possible recovery treatment - using ibogaine and other psychedelic medicines - to enable them to be free from addiction and to flourish
Opioid addiction has reached epidemic levels in Canada, the United States and worldwide. Opioid and heroin is now the #1 cause of accidental death in Canada and the US for people under 50. At all stages, it destroys families. The opioid crisis cost the US $696 billion in 2018 - or 3.4 percent of GDP - and more than $2.5 trillion for the four - year period from 2015 to 2018.
Our team is made up of proven entrepreneurs and business leaders who have benefitted from transformative therapies in their own lives. We've been the pioneers of ibogaine treatment and have completed thousands of treatments.
Learn More
U.S. states claimed they are owed $2.2 trillion to address harm from OxyContin maker Purdue Pharma LP’s alleged role in America’s opioid epidemic, accusing the drugmaker in new filings of pushing prescription painkillers on doctors and patients while playing down the risks of abuse and overdose.
View More
The opioid crisis has created a pressing need for successful addiction treatments, especially as the majority of people who seek treatment are highly likely to relapse.In today’s episode, we speak with Founder and Co-Chairman, Shayne Nyquvest and CEO, Jeremy Weate at Universal Ibogaine.
View More
2020 Psychedelics Industry Insights Report Nikita Alexandrov BChem, MBA-CTO,ThinkMyco Jan 11th, 2020 2019 was a pivotal year in the psychedelic industry with US decriminalization actions, two companies receiving FDA breakthrough status for psilocybin, funding of the $16M Johns Hopkins Psychedelic Research Center,The US Defence Department starting their rumored $20M+ Focused Pharma psychedelic science program and ...
View MoreBy requesting access you'll be able to hear about our PRE-IPO investment opportunities and key milestones that our company achieves! Get the inside scoop on the largest psychedelic investment opportunity
Sign UpOops! Something went wrong while submitting the form
